Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Evoke Pharma (EVOK)

Evoke Pharma (EVOK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 61,831
  • Shares Outstanding, K 32,372
  • Annual Sales, $ 20 K
  • Annual Income, $ -13,150 K
  • 60-Month Beta 1.13
  • Price/Sales 2,674.21
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade EVOK with:

Options Overview

Details
  • Implied Volatility 149.23%
  • Historical Volatility 60.49%
  • IV Percentile 54%
  • IV Rank 29.37%
  • IV High 292.95% on 12/07/20
  • IV Low 89.47% on 08/12/20
  • Put/Call Vol Ratio 0.03
  • Today's Volume 40
  • Volume Avg (30-Day) 323
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 19,754
  • Open Int (30-Day) 12,382

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.06
  • Number of Estimates 1
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year -0.07
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6800 +1.19%
on 04/14/21
2.6300 -35.36%
on 03/16/21
-0.7500 (-30.61%)
since 03/12/21
3-Month
1.6800 +1.19%
on 04/14/21
4.8000 -64.58%
on 02/09/21
-1.2100 (-41.58%)
since 01/14/21
52-Week
1.1000 +54.55%
on 04/23/20
6.0628 -71.96%
on 08/11/20
+0.4500 (+36.00%)
since 04/14/20

Most Recent Stories

More News
Evoke Pharma Receives Notice of Allowance from United States Patent and Trademark Office for a Method of Use Patent with Claims Covering Gimoti(R)

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the United States Patent and Trademark Office (USPTO)...

EVOK : 1.7000 (-2.30%)
Evoke Pharma Announces a Fireside Chat with Key Opinion Leaders on the Treatment of Gastroparesis

Evoke Pharma, Inc. (Nasdaq: EVOK), a commercial stage specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that Yale Jen, Senior Biotech...

EVOK : 1.7000 (-2.30%)
Evoke Pharma, Inc. (EVOK) Reports Q4 Loss, Misses Revenue Estimates

Evoke Pharma, Inc. (EVOK) delivered earnings and revenue surprises of -125.00% and -98.08%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?...

EVOK : 1.7000 (-2.30%)
Evoke Pharma Reports Fourth Quarter and Full Year 2020 Financial Results

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter ended...

EVOK : 1.7000 (-2.30%)
Evoke Pharma, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 11, 2021 / Evoke Pharma, Inc. (NASDAQ:EVOK) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 11, 2021 at 4:30 PM...

EVOK : 1.7000 (-2.30%)
Evoke Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021

Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that the Company is scheduled to release its...

EVOK : 1.7000 (-2.30%)
Evoke Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares

Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, announced today the completion of its follow-on offering of...

EVOK : 1.7000 (-2.30%)
Evoke Pharma Announces Pricing of Public Offering of Common Stock

Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that it has priced an underwritten public offering...

EVOK : 1.7000 (-2.30%)
Evoke Pharma Announces Proposed Public Offering of Common Stock

Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that it intends to offer and sell shares of...

EVOK : 1.7000 (-2.30%)
Evoke Pharma Announces Positive Findings from GIMOTI(TM) Market Research Study

Evoke Pharma, Inc. ("Evoke" or the "Company") (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced positive findings...

EVOK : 1.7000 (-2.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke...

See More

Key Turning Points

3rd Resistance Point 1.8933
2nd Resistance Point 1.8467
1st Resistance Point 1.7733
Last Price 1.7000
1st Support Level 1.6533
2nd Support Level 1.6067
3rd Support Level 1.5333

See More

52-Week High 6.0628
Fibonacci 61.8% 4.1670
Fibonacci 50% 3.5814
Fibonacci 38.2% 2.9958
Last Price 1.7000
52-Week Low 1.1000

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar